Health
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas – News-Medical.Net
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
General17 hours agoAccused of Antisemitism: Herald Sun, Israel lobby v Dandenong Clr Rhonda Garad
-
Noosa News17 hours agoMitch Power Quick Shear event gets men talking about mental health
-
Business16 hours agoAdd these 2 satellite ETFs to your core ASX stock portfolio
-
General19 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why